| Literature DB >> 30595477 |
Anne-Sophie Wedell-Neergaard1, Louise Lang Lehrskov1, Regitse Højgaard Christensen1, Grit Elster Legaard1, Emma Dorph1, Monica Korsager Larsen1, Natja Launbo1, Sabrina Ravn Fagerlind1, Sidsel Kofoed Seide1, Stine Nymand1, Maria Ball1, Nicole Vinum1, Camilla Noerfelt Dahl1, Marie Henneberg1, Mathias Ried-Larsen1, Janus Damm Nybing2, Robin Christensen3, Jaya Birgitte Rosenmeier4, Kristian Karstoft1, Bente Klarlund Pedersen1, Helga Ellingsgaard5, Rikke Krogh-Madsen1.
Abstract
Visceral adipose tissue is harmful to metabolic health. Exercise training reduces visceral adipose tissue mass, but the underlying mechanisms are not known. Interleukin-6 (IL-6) stimulates lipolysis and is released from skeletal muscle during exercise. We hypothesized that exercise-induced reductions in visceral adipose tissue mass are mediated by IL-6. In this randomized placebo-controlled trial, we assigned abdominally obese adults to tocilizumab (IL-6 receptor antibody) or placebo during a 12-week intervention with either bicycle exercise or no exercise. While exercise reduced visceral adipose tissue mass, this effect of exercise was abolished in the presence of IL-6 blockade. Changes in body weight and total adipose tissue mass showed similar tendencies, whereas lean body mass did not differ between groups. Also, IL-6 blockade increased cholesterol levels, an effect not reversed by exercise. Thus, IL-6 is required for exercise to reduce visceral adipose tissue mass and emphasizes a potentially important metabolic consequence of IL-6 blockade.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30595477 DOI： 10.1016/j.cmet.2018.12.007
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287